Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models
Erica Zamberletti, Marina Gabaglio, Daniela Parolaro
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 9, pp. 1916-1916
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study
Adi Aran, Hanoch Cassuto, Asael Lubotzky, et al.
Journal of Autism and Developmental Disorders (2018) Vol. 49, Iss. 3, pp. 1284-1288
Closed Access | Times Cited: 173
Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy
Lihi Bar‐Lev Schleider, Raphael Mechoulam, Naama Saban, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 147
Cannabinoid treatment for autism: a proof-of-concept randomized trial
Adi Aran, Moria Harel, Hanoch Cassuto, et al.
Molecular Autism (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 140
Plasma anandamide concentrations are lower in children with autism spectrum disorder
Debra S. Karhson, Karolina Krasinska, Jamie Ahloy‐Dallaire, et al.
Molecular Autism (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 129
Lower circulating endocannabinoid levels in children with autism spectrum disorder
Adi Aran, Maya Eylon, Moria Harel, et al.
Molecular Autism (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 124
Sex‐specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling
Francesca Melancia, Sara Schiavi, Michela Servadio, et al.
British Journal of Pharmacology (2018) Vol. 175, Iss. 18, pp. 3699-3712
Open Access | Times Cited: 118
Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment
Marika Premoli, Francesca Aria, Sara Anna Bonini, et al.
Life Sciences (2019) Vol. 224, pp. 120-127
Closed Access | Times Cited: 114
Prenatal paracetamol exposure and child neurodevelopment: A review
Ann Z. Bauer, David Kriebel, Martha R. Herbert, et al.
Hormones and Behavior (2018) Vol. 101, pp. 125-147
Closed Access | Times Cited: 108
Cannabidiol as a suggested candidate for treatment of autism spectrum disorder
Shani Poleg, Pavel Golubchik, Daniel Offen, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018) Vol. 89, pp. 90-96
Closed Access | Times Cited: 105
Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives
Alison C. Burggren, Anaheed Shirazi, Nathaniel D. Ginder, et al.
The American Journal of Drug and Alcohol Abuse (2019) Vol. 45, Iss. 6, pp. 563-579
Open Access | Times Cited: 100
The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids
Keith Cheung, Hassendrini N. Peiris, Geoff Wallace, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 23, pp. 6079-6079
Open Access | Times Cited: 91
Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats
Erica Zamberletti, Marina Gabaglio, Marie Woolley-Roberts, et al.
Frontiers in Cellular Neuroscience (2019) Vol. 13
Open Access | Times Cited: 82
The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets
Rosa Maria Vitale, Fabio Arturo Iannotti, Pietro Amodeo
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4876-4876
Open Access | Times Cited: 62
Mouse and rat ultrasonic vocalizations in neuroscience and neuropharmacology: State of the art and future applications
Marika Premoli, Susanna Pietropaolo, Markus Wöhr, et al.
European Journal of Neuroscience (2023) Vol. 57, Iss. 12, pp. 2062-2096
Open Access | Times Cited: 40
Can Memantine Treat Autism? Answers from Preclinical and Clinical Studies
Sawsan Aboul‐Fotouh, Sohir M Zohny, Esraa M. Elnahas, et al.
Neuroscience & Biobehavioral Reviews (2025) Vol. 169, pp. 106019-106019
Closed Access | Times Cited: 1
Presynaptic dysfunction in neurodevelopmental disorders: Insights from the synaptic vesicle life cycle
Katherine Bonnycastle, Elizabeth C. Davenport, Michael A. Cousin
Journal of Neurochemistry (2020) Vol. 157, Iss. 2, pp. 179-207
Open Access | Times Cited: 67
Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies
Laura Fusar‐Poli, Vito Cavone, Silvia Tinacci, et al.
Brain Sciences (2020) Vol. 10, Iss. 9, pp. 572-572
Open Access | Times Cited: 66
The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
Vincenzo Di Marzo
Dialogues in Clinical Neuroscience (2020) Vol. 22, Iss. 3, pp. 259-269
Open Access | Times Cited: 61
Medical Cannabis in Children
Adi Aran, Dalit Cayam-Rand
Rambam Maimonides Medical Journal (2020) Vol. 11, Iss. 1, pp. e0003-e0003
Open Access | Times Cited: 58
Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission?
Pierangelo Cifelli, Gabriele Ruffolo, Eleonora De Felice, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 3, pp. 723-723
Open Access | Times Cited: 52
FMR1 and Autism, an Intriguing Connection Revisited
William Fyke, Milen Velinov
Genes (2021) Vol. 12, Iss. 8, pp. 1218-1218
Open Access | Times Cited: 42
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
João Francisco Cordeiro Pedrazzi, Frederico Rogério Ferreira, Danyelle Silva-Amaral, et al.
Psychopharmacology (2022) Vol. 239, Iss. 9, pp. 2713-2734
Closed Access | Times Cited: 31
A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ
Aviad Schnapp, Moria Harel, Dalit Cayam-Rand, et al.
Biomedicines (2022) Vol. 10, Iss. 7, pp. 1685-1685
Open Access | Times Cited: 29
A systematic review of cannabidiol trials in neurodevelopmental disorders
Nina-Francecsa Parrella, Aron T. Hill, Peter G. Enticott, et al.
Pharmacology Biochemistry and Behavior (2023) Vol. 230, pp. 173607-173607
Open Access | Times Cited: 18
Cannabinoid treatment for the symptoms of autism spectrum disorder
Adi Aran, Dalit Cayam Rand
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 1, pp. 65-79
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top